INTRODUCTION: There is increasing interest in the relationship between cannabinoids and psychosis. While individual human laboratory studies have been critical in demonstrating that cannabinoids (e.g., delta-9-tetrahydrocannabinol [THC]) can induce acute transient psychosis-like effects in healthy human volunteers, combining data from multiple studies offers a fine-grained view of these effects. METHODS:THC-induced psychosis-relevant effects were examined using a data repository of 10 double-blind, randomized, placebo-controlled, crossover studies with 400 i.v. THC infusions in healthy human volunteers. The Positive and Negative Syndrome scale was used to measure psychotomimetic effects. The profile of symptoms, frequency of a response, its relationship to THC dose and substance use, latent structure in Positive and Negative Syndrome scale response, and the relationships between psychotomimetic and perceptual alteration symptoms were evaluated. RESULTS: Clinically meaningful increases in positive symptoms were noted in 44.75% infusions; conceptual disorganization, hallucinations, blunted affect, somatic concern, motor retardation, and poor attention were the items most frequently altered by THC. The increase in Positive and Negative Syndrome scale positive symptoms was positively associated with THC dose (beta = 11.13, SE = 4.94, Wald χ 2 = 19.88, P < .001) and negatively associated with frequent cannabis use (beta = -0.575, SE = 0.14, Wald χ 2 = 18.13, P < .001). Furthermore, positive symptoms were strongly correlated with Clinician Administered Dissociative States Scale perceptual alterations score (rs = 0.514, P < .001). CONCLUSION: Intravenous administration of THC consistently induces psychotomimetic effects that include symptoms across Positive and Negative Syndrome scale domains. Moreover, healthy individuals who frequently use cannabis have a blunted psychotomimetic response. Published by Oxford University Press on behalf of CINP 2020.
RCT Entities:
INTRODUCTION: There is increasing interest in the relationship between cannabinoids and psychosis. While individual human laboratory studies have been critical in demonstrating that cannabinoids (e.g., delta-9-tetrahydrocannabinol [THC]) can induce acute transient psychosis-like effects in healthy human volunteers, combining data from multiple studies offers a fine-grained view of these effects. METHODS:THC-induced psychosis-relevant effects were examined using a data repository of 10 double-blind, randomized, placebo-controlled, crossover studies with 400 i.v. THC infusions in healthy human volunteers. The Positive and Negative Syndrome scale was used to measure psychotomimetic effects. The profile of symptoms, frequency of a response, its relationship to THC dose and substance use, latent structure in Positive and Negative Syndrome scale response, and the relationships between psychotomimetic and perceptual alteration symptoms were evaluated. RESULTS: Clinically meaningful increases in positive symptoms were noted in 44.75% infusions; conceptual disorganization, hallucinations, blunted affect, somatic concern, motor retardation, and poor attention were the items most frequently altered by THC. The increase in Positive and Negative Syndrome scale positive symptoms was positively associated with THC dose (beta = 11.13, SE = 4.94, Wald χ 2 = 19.88, P < .001) and negatively associated with frequent cannabis use (beta = -0.575, SE = 0.14, Wald χ 2 = 18.13, P < .001). Furthermore, positive symptoms were strongly correlated with Clinician Administered Dissociative States Scale perceptual alterations score (rs = 0.514, P < .001). CONCLUSION: Intravenous administration of THC consistently induces psychotomimetic effects that include symptoms across Positive and Negative Syndrome scale domains. Moreover, healthy individuals who frequently use cannabis have a blunted psychotomimetic response. Published by Oxford University Press on behalf of CINP 2020.
Entities:
Keywords:
PANSS; cannabinoid; delta-9-THC; human laboratory model; psychosis; schizophrenia
Authors: Joëlle A Pasman; Karin J H Verweij; Zachary Gerring; Sven Stringer; Sandra Sanchez-Roige; Jorien L Treur; Abdel Abdellaoui; Michel G Nivard; Bart M L Baselmans; Jue-Sheng Ong; Hill F Ip; Matthijs D van der Zee; Meike Bartels; Felix R Day; Pierre Fontanillas; Sarah L Elson; Harriet de Wit; Lea K Davis; James MacKillop; Jaime L Derringer; Susan J T Branje; Catharina A Hartman; Andrew C Heath; Pol A C van Lier; Pamela A F Madden; Reedik Mägi; Wim Meeus; Grant W Montgomery; A J Oldehinkel; Zdenka Pausova; Josep A Ramos-Quiroga; Tomas Paus; Marta Ribases; Jaakko Kaprio; Marco P M Boks; Jordana T Bell; Tim D Spector; Joel Gelernter; Dorret I Boomsma; Nicholas G Martin; Stuart MacGregor; John R B Perry; Abraham A Palmer; Danielle Posthuma; Marcus R Munafò; Nathan A Gillespie; Eske M Derks; Jacqueline M Vink Journal: Nat Neurosci Date: 2018-08-27 Impact factor: 24.884
Authors: Emma Barkus; Paul D Morrison; D Vuletic; John C Dickson; Peter J Ell; Lyn S Pilowsky; Rudolf Brenneisen; David W Holt; John Powell; Shitij Kapur; Robin M Murray Journal: J Psychopharmacol Date: 2010-09-17 Impact factor: 4.153
Authors: Deepak Cyril D'Souza; Edward Perry; Lisa MacDougall; Yola Ammerman; Thomas Cooper; Yu-Te Wu; Gabriel Braley; Ralitza Gueorguieva; John Harrison Krystal Journal: Neuropsychopharmacology Date: 2004-08 Impact factor: 7.853
Authors: Anissa Abi-Dargham; Elsmarieke van de Giessen; Mark Slifstein; Lawrence S Kegeles; Marc Laruelle Journal: Biol Psychiatry Date: 2009-01-23 Impact factor: 13.382
Authors: Robert C Smith; Henry Sershen; David S Janowsky; Abel Lajtha; Matthew Grieco; Jon A Gangoiti; Ilya Gertsman; Wynnona S Johnson; Thomas D Marcotte; John M Davis Journal: Front Psychiatry Date: 2022-07-04 Impact factor: 5.435
Authors: Russell C Callaghan; Marcos Sanches; Robin M Murray; Sarah Konefal; Bridget Maloney-Hall; Stephen J Kish Journal: Can J Psychiatry Date: 2022-01-12 Impact factor: 5.321